98.00

1.92% 1.85

After Hours: 97.50 -0.50 -0.51%

Nuvalent Inc (NUVL)

Overview News Price History Option Chain Financials Why NUVL Down? Discussions Forecast

Nuvalent Inc stock is traded at $98.00, with a volume of 698.35K. It is up +1.92% in the last 24 hours and down -6.25% over the past month. Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Previous Close:

$96.15

Open:

$97.47

24h Volume:

698.35K

Relative Volume:

1.33

Market Cap:

$7.70B

Revenue:

Net Income/Loss:

$-425.38M

P/E Ratio:

-16.75

EPS:

-5.8504

Net Cash Flow:

$-275.21M

1W Performance:

+0.59%

1M Performance:

-6.25%

6M Performance:

+26.42%

1Y Performance:

+30.70%

1-Day Range:

$97.08

$100.67

1-Week Range:

$93.91

$100.67

52-Week Range:

$55.53

$113.02

Nuvalent Inc Stock (NUVL) Company Profile

Name

Nuvalent Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

508-446-2272

Address

ONE BROADWAY, 14TH FLOOR, CAMBRIDGE

Employee

228

Twitter

Next Earnings Date

Latest SEC Filings

NUVL's Discussions on Twitter

Compare NUVL vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVL Nuvalent Inc	98.00	7.56B	0	-425.38M	-275.21M	-5.8504
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Nuvalent Inc Stock (NUVL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-24-25	Initiated	Truist	Buy
Nov-12-25	Initiated	Canaccord Genuity	Buy
Oct-16-25	Resumed	Stifel	Buy
Oct-15-25	Initiated	Cantor Fitzgerald	Overweight
Sep-04-25	Resumed	Guggenheim	Buy
Sep-03-25	Initiated	Raymond James	Outperform
Aug-19-25	Initiated	Piper Sandler	Overweight
Mar-14-25	Upgrade	UBS	Neutral → Buy
Dec-30-24	Initiated	H.C. Wainwright	Buy
Oct-24-24	Initiated	UBS	Neutral
Aug-29-24	Initiated	Barclays	Overweight
Apr-17-24	Initiated	Jefferies	Buy
Apr-01-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-28-24	Resumed	Guggenheim	Buy
Feb-23-24	Initiated	Robert W. Baird	Outperform
Sep-27-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	SVB Securities	Market Perform
Jul-24-23	Initiated	Guggenheim	Buy
Jan-18-23	Initiated	Wedbush	Outperform
Jun-24-22	Initiated	BMO Capital Markets	Outperform

View All

Nuvalent Inc Stock (NUVL) Latest News

Mar 24, 2026

NUVL (NASDAQ: NUVL) files Form 144 to sell Class A shares via J.P. Morgan - Stock Titan

Mar 24, 2026

Mar 23, 2026

Hudson Bay Capital Management LP Acquires Stake in Nuvalent, Inc. - National Today

Mar 23, 2026

Hudson Bay Capital Management LP Purchases New Stake in Nuvalent, Inc. $NUVL - MarketBeat

Mar 23, 2026

Mar 22, 2026

Stop Loss: Should I set a stop loss on Nuvalent Inc2026 Volume & Capital Protection Trade Alerts - baoquankhu1.vn

Mar 22, 2026

Trend Report: Is Nuvalent Inc in a consolidation phase2026 Retail & Weekly Return Optimization Alerts - baoquankhu1.vn

Mar 22, 2026

Aug Catalysts: Is Nuvalent Inc in a consolidation phase2026 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn

Mar 22, 2026

Mar 20, 2026

Nuvalent (NUVL) officer Benjamin Lane details stock, options and RSUs in Form 3 - Stock Titan

Mar 20, 2026

(NUVL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Mar 20, 2026

Mar 19, 2026

FDA Review of Zidesamtinib Data Might Change The Case For Investing In Nuvalent (NUVL) - Yahoo Finance

Mar 19, 2026

Cantor Fitzgerald L. P. Makes New $1.95 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat

Mar 19, 2026

Mar 18, 2026

Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN

Mar 18, 2026

Mar 17, 2026

Nuvalent to unveil new ROS1+ NSCLC clinical and preclinical data at AACR 2026 - Traders Union

Mar 17, 2026

Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 - PR Newswire

Mar 17, 2026

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - AOL.com

Mar 17, 2026

Vestal Point Sells Nuvalent Shares: Portfolio Impact and Company OutlookNews and Statistics - IndexBox

Mar 17, 2026

Nuvalent (NUVL) Gets a Buy from Canaccord Genuity - The Globe and Mail

Mar 17, 2026

Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Mar 17, 2026

Mar 16, 2026

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - The Motley Fool

Mar 16, 2026

Nuvalent's Chief Scientific Officer Sells Over 35,000 Shares - TradingView

Mar 16, 2026

Nuvalent (NUVL) CSO sells 35,104 shares after major option exercises - Stock Titan

Mar 16, 2026

Nuvalent, Inc. Holdings Raised by HighVista Strategies LLC - National Today

Mar 16, 2026